Showing results (71-80 of 107) with videos related to
Sort By:
Pageof 11
Neoplasia (New York, N.Y.)|July 31, 2021
A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinomaEri Munekage, Satoshi Serada, Shigehiro Tsujii, et al.Journal of Crohn'S & Colitis|July 29, 2016
Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative ColitisShinichiro Shinzaki, Katsuyoshi Matsuoka, Hideki Iijima, et al.British Journal of Cancer|February 19, 2016
Similar protein expression profiles of ovarian and endometrial high-grade serous carcinomasKosuke Hiramatsu, Kiyoshi Yoshino, Satoshi Serada, et al.Cardiovascular Research|May 31, 2011
IL-6-mediated Th17 differentiation through RORγt is essential for the initiation of experimental autoimmune myocarditisTomomi Yamashita, Tomohiko Iwakura, Kazuki Matsui, et al.Cancer Science|December 22, 2018
Epithelial-mesenchymal transition via transforming growth factor beta in pancreatic cancer is potentiated by the inflammatory glycoprotein leucine-rich alpha-2 glycoproteinToru Otsuru, Shogo Kobayashi, Hiroshi Wada, et al.Plos One|November 19, 2020
Evaluation of leucine-rich alpha-2 glycoprotein as a biomarker of fetal infectionEtsuko Kajimoto, Masayuki Endo, Minoru Fujimoto, et al.Immunity|November 16, 2002
SOCS-1 participates in negative regulation of LPS responsesReiko Nakagawa, Tetsuji Naka, Hiroko Tsutsui, et al.Proceedings of the National Academy of Sciences of the United States of America|June 26, 2008
IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitisSatoshi Serada, Minoru Fujimoto, Masahiko Mihara, et al.International Journal of Cancer|October 24, 2013
Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7AShinya Matsuzaki, Takayuki Enomoto, Satoshi Serada, et al.Molecular Cancer Therapeutics|July 5, 2021
Anti-Glypican-1 Antibody-drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1-Positive CholangiocarcinomaKeiichiro Yokota, Satoshi Serada, Shigehiro Tsujii, et al.Pageof 11